EA201791294A1 - 7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ - Google Patents

7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Info

Publication number
EA201791294A1
EA201791294A1 EA201791294A EA201791294A EA201791294A1 EA 201791294 A1 EA201791294 A1 EA 201791294A1 EA 201791294 A EA201791294 A EA 201791294A EA 201791294 A EA201791294 A EA 201791294A EA 201791294 A1 EA201791294 A1 EA 201791294A1
Authority
EA
Eurasian Patent Office
Prior art keywords
morfolinil
methyltieno
anticative
piperasinyl
medicines
Prior art date
Application number
EA201791294A
Other languages
English (en)
Other versions
EA036819B1 (ru
Inventor
Дурга Прасад Конаканчи
Субба Рао Пула
Рама Кришна Пилли
Лакшмана Висва Венката Паван Кумар Маддула
Сриниваса Кришна Муртхи Кондури
Джанаки Рама Рао Рави
Нага Васанта Сринивасу Вуппалапати
Сандип Кумар Тхоота
Пулла Редди Муддасани
Кали Сатья Бхуджанга Рао Адибхатла
Венкайах Човдари Наннапанени
Original Assignee
Натко Фарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Натко Фарма Лимитед filed Critical Натко Фарма Лимитед
Publication of EA201791294A1 publication Critical patent/EA201791294A1/ru
Publication of EA036819B1 publication Critical patent/EA036819B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к новому ряду замещенных 7-(морфолинил)-2-(N-пиперазинил)метилтиено[2,3-c]пиридинов следующей структуры формулы Iгде R, R, Rи Rимеют указанное в описании изобретения значение.
EA201791294A 2014-12-11 2014-12-11 7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ EA036819B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2014/000770 WO2016092556A1 (en) 2014-12-11 2014-12-11 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Publications (2)

Publication Number Publication Date
EA201791294A1 true EA201791294A1 (ru) 2017-11-30
EA036819B1 EA036819B1 (ru) 2020-12-23

Family

ID=52595387

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791294A EA036819B1 (ru) 2014-12-11 2014-12-11 7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Country Status (31)

Country Link
US (1) US10106554B2 (ru)
EP (1) EP3230289B1 (ru)
JP (1) JP6454419B2 (ru)
KR (1) KR102328921B1 (ru)
CN (1) CN107074873B (ru)
AP (1) AP2017009749A0 (ru)
AU (1) AU2014413483B2 (ru)
BR (1) BR112017005518B1 (ru)
CA (1) CA2959980C (ru)
CO (1) CO2017002266A2 (ru)
CY (1) CY1122080T1 (ru)
DK (1) DK3230289T3 (ru)
EA (1) EA036819B1 (ru)
ES (1) ES2750268T3 (ru)
HR (1) HRP20192041T1 (ru)
HU (1) HUE047144T2 (ru)
IL (1) IL252254B (ru)
LT (1) LT3230289T (ru)
MA (1) MA40110B2 (ru)
MX (1) MX2017004782A (ru)
MY (1) MY188946A (ru)
NZ (1) NZ729078A (ru)
PH (1) PH12017500342A1 (ru)
PL (1) PL3230289T3 (ru)
PT (1) PT3230289T (ru)
RS (1) RS59409B1 (ru)
SG (1) SG11201702162PA (ru)
SI (1) SI3230289T1 (ru)
UA (1) UA117318C2 (ru)
WO (1) WO2016092556A1 (ru)
ZA (1) ZA201701036B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221905A1 (es) * 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
KR20220119651A (ko) 2019-12-20 2022-08-30 바이엘 악티엔게젤샤프트 치환된 티오펜 카르복스아미드, 티오펜 카르복실산 및 그의 유도체
AU2022260846A1 (en) * 2021-04-21 2023-11-16 Natco Pharma Limited Improved process for the preparation of 7-(morpholinyl)-2-(n-piperazinyl)methylthieno[2, 3-c]pyridine derivatives
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579526A (en) 1968-11-13 1971-05-18 Research Corp Preparation of thienopyridines
FR2411838A1 (fr) 1977-12-19 1979-07-13 Parcor Nouveaux derives des thieno (2-3-c) et (3,2-c) pyridines, leurs procede de preparation et leur application therapeutique
US4839365A (en) 1987-05-19 1989-06-13 Shinogi & Co., Ltd. Thienopyridine derivatives useful in treating gastric ulcers
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2007537296A (ja) * 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
GB0608264D0 (en) * 2006-04-26 2006-06-07 Piramed Ltd Pharmaceutical compounds
US8252792B2 (en) 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
ES2537352T3 (es) * 2007-09-12 2015-06-05 Genentech, Inc. Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
GB0723748D0 (en) 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
CL2009000780A1 (es) 2008-03-31 2010-01-15 Genentech Inc Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
TWI558710B (zh) * 2009-01-08 2016-11-21 古利斯股份有限公司 具有鋅連接部位的磷酸肌醇３－激酶抑制劑
AU2010300719A1 (en) * 2009-09-29 2012-05-03 Xcovery Holding Company Llc PI3K (delta) selective inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
US8653089B2 (en) 2011-02-09 2014-02-18 F. Hoffmann-La Roche Ag Heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
AU2014413483A1 (en) 2017-03-09
BR112017005518A2 (pt) 2017-12-05
US10106554B2 (en) 2018-10-23
EP3230289A1 (en) 2017-10-18
CA2959980A1 (en) 2016-06-16
CN107074873A (zh) 2017-08-18
DK3230289T3 (da) 2019-10-28
US20170320891A1 (en) 2017-11-09
SG11201702162PA (en) 2017-04-27
MY188946A (en) 2022-01-14
NZ729078A (en) 2021-07-30
PT3230289T (pt) 2019-10-30
WO2016092556A1 (en) 2016-06-16
CY1122080T1 (el) 2020-11-25
KR102328921B1 (ko) 2021-11-19
PH12017500342A1 (en) 2017-07-17
MX2017004782A (es) 2017-07-27
ZA201701036B (en) 2019-06-26
KR20170090434A (ko) 2017-08-07
JP6454419B2 (ja) 2019-01-16
CN107074873B (zh) 2022-01-07
HRP20192041T1 (hr) 2020-02-07
MA40110B2 (fr) 2020-12-31
JP2017537139A (ja) 2017-12-14
HUE047144T2 (hu) 2020-04-28
ES2750268T3 (es) 2020-03-25
EP3230289B1 (en) 2019-08-14
BR112017005518B1 (pt) 2022-11-29
RS59409B1 (sr) 2019-11-29
SI3230289T1 (sl) 2019-10-30
EA036819B1 (ru) 2020-12-23
AP2017009749A0 (en) 2017-02-28
CO2017002266A2 (es) 2017-05-31
LT3230289T (lt) 2019-10-10
IL252254B (en) 2019-08-29
AU2014413483B2 (en) 2019-07-25
UA117318C2 (uk) 2018-07-10
MA40110A1 (fr) 2017-12-29
CA2959980C (en) 2023-04-25
PL3230289T3 (pl) 2020-03-31
IL252254A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
CO2017007663A2 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
AU2015237050A8 (en) Quinoline derivatives as SMO inhibitors
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
TR201909887T4 (tr) ERK inhibitörleri olarak tieno[2,3-c]pirol-4-on türevleri.
MX2020005181A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
EA201691194A1 (ru) Стимуляторы ргц
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
CY1122080T1 (el) 7-(μορφολινυλ)-2-(n-πιπεραζινυλ) μεθυλοθειαινο [2,3-c]πυριδινης ως αντικαρκινικα φαρμακα
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
EA201890821A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12016502293A1 (en) Naphthyridinedione derivatives
PH12018502376B1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
EA201700037A1 (ru) Производные 2н-хромена в качестве анальгезирующих средств